Two cases of renal cell carcinoma harboring a novel STRN-ALK fusion gene

American Journal of Surgical Pathology

Volumn 40, Issue 6, 2016, Pages 761-769

  Kusano, Hironori ^a   Togashi, Yuki ^b,c   Akiba, Jun ^a   Moriya, Fukuko ^a   Baba, Katsuyoshi ^d   Matsuzaki, Naomi ^e   Yuba, Yoshiaki ^e   Shiraishi, Yusuke ^e   Kanamaru, Hiroshi ^e   Kuroda, Naoto ^f   Sakata, Seiji ^b   Takeuchi, Kengo ^b,c   Yano, Hirohisa ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Shin Koga Hospital   (Japan)

^c CANCER INSTITUTE   (Japan)

^d CANCER INSTITUTE HOSPITAL   (Japan)

^e Kitano Hospital   (Japan)

^f KOCHI RED CROSS HOSPITAL   (Japan)

Author keywords

Anaplastic lymphoma kinase; Renal cell carcinoma; Striatin

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CALMODULIN BINDING PROTEIN; MEMBRANE PROTEIN; NERVE PROTEIN; ONCOPROTEIN; PROTEIN TYROSINE KINASE; STRN PROTEIN, HUMAN;

ADULT; CASE REPORT; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FUSION; GENETICS; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; PATHOLOGY; TUMOR RECURRENCE;

ADULT; CALMODULIN-BINDING PROTEINS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KIDNEY NEOPLASMS; MALE; MEMBRANE PROTEINS; NEOPLASM RECURRENCE, LOCAL; NERVE TISSUE PROTEINS; ONCOGENE FUSION; ONCOGENE PROTEINS, FUSION; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84957676733     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000610     Document Type: Article

References (34)

1. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science. 1994;263:1281-1284.
2. Hallberg B, Palmer RH. Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat Rev Cancer. 2013;13: 685-700.
3. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693-1703.
4. Debelenko LV, Raimondi SC, Daw N, et al. Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum. Mod Pathol. 2011;24:430-442.
5. Marino-Enriquez A, Ou WB, Weldon CB, et al. ALK rearrangement in sickle cell trait-associated renal medullary carcinoma. Genes Chromosomes Cancer. 2011;50:146-153.
6. Sugawara E, Togashi Y, Kuroda N, et al. Identification of anaplastic lymphoma kinase fusions in renal cancer. Cancer. 2012; 118:4427-4436.
7. Sukov WR, Hodge JC, Lohse CM, et al. ALK alterations in adult renal cell carcinoma: frequency, clinicopathologic features and outcome in a large series of consecutively treated patients. Mod Pathol. 2012;25:1516-1525.
8. Lee C, Park JW, Suh JH, et al. ALK-positive renal cell carcinoma in a large series of consecutively resected Korean renal cell carcinoma patients. Korean J Pathol. 2013;47:452-457.
9. Smith NE, Deyrup AT, Marino-Enriquez A, et al. VCL-ALK renal cell carcinoma in children with sickle-cell trait: the eighth sickle-cell nephropathy? Am J Surg Pathol. 2014;38:858-863.
10. Eble JN, Sauter G, Epstein JI, et al. World Health Organization Classification of Tumours Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC; 2004.
11. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6:655-663.
12. Togashi Y, Soda M, Sakata S, et al. KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS One. 2012;7:e31323.
13. Majewski IJ, Mittempergher L, Davidson NM, et al. Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing. J Pathol. 2013;230:270-276.
14. Kelly LM, Barila G, Liu P, et al. Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. Proc Natl Acad Sci USA. 2014;111:4233-4238.
15. Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopa-thologic and immunohistochemical study of 105 tumors. Mod Pathol. 1997;10:537-544.
16. Renshaw AA, Zhang H, Corless CL, et al. Solid variants of papillary (chromophil) renal cell carcinoma: clinicopathologic and genetic features. Am J Surg Pathol. 1997;21:1203-1209.
17. Srigley JR, Delahunt B, Eble JN, et al. The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol. 2013;37:1469-1489.
18. Martignoni G, Pea M, Gobbo S, et al. Cathepsin-K immuno-reactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas. Mod Pathol. 2009;22:1016-1022.
19. Smith NE, Illei PB, Allaf M, et al. t(6;11) renal cell carcinoma (RCC): expanded immunohistochemical profile emphasizing novel RCC markers and report of 10 new genetically confirmed cases. Am J Surg Pathol. 2014;38:604-614.
20. Argani P, Lal P, Hutchinson B, et al. Aberrant nuclear immunor-eactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. Am J Surg Pathol. 2003; 27:750-761.
21. Argani P, Lae M, Hutchinson B, et al. Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR. Am J Surg Pathol. 2005;29:230-240.
22. Ohe C, Kuroda N, Pan CC, et al. A unique renal cell carcinoma with features of papillary renal cell carcinoma and thyroid-like carcinoma: a morphological, immunohistochemical and genetic study. Histopathology. 2010;57:494-497.
23. Amin MB, Gupta R, Ondrej H, et al. Primary thyroid-like follicular carcinoma of the kidney: report of 6 cases of a histologically distinctive adult renal epithelial neoplasm. Am J Surg Pathol. 2009; 33:393-400.
24. Jokoji R, Yamasaki T, Minami S, et al. Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma. J Clin Pathol. 2010;63:1066-1070.
25. Yoshida A, Tsuta K, Nakamura H, et al. Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol. 2011;35:1226-1234.
26. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012;18:378-381.
27. McFadden DG, Dias-Santagata D, Sadow PM, et al. Identification of oncogenic mutations and gene fusions in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2014;99: E2457-E2462.
28. Perot G, Soubeyran I, Ribeiro A, et al. Identification of a recurrent STRN/ALK fusion in thyroid carcinomas. PLoS One. 2014; 9:e87170.
29. Demeure MJ, Aziz M, Rosenberg R, et al. Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified EML4-ALK translocation as a therapeutic target. World J Surg. 2014;38:1296-1305.
30. The Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159: 676-690.
31. Chou A, Fraser S, Toon CW, et al. A detailed clinicopathologic study of ALK-translocated papillary thyroid carcinoma. Am J Surg Pathol. 2015;39:652-659.
32. Ji JH, Oh YL, Hong M, et al. Identification of driving ALK fusion genes and genomic landscape of medullary thyroid cancer. PLoS Genet. 2015;11:e1005467.
33. Conklin CM, Craddock KJ, Have C, et al. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. J Thorac Oncol. 2013;8:45-51.
34. Godbert Y, Henriques de Figueiredo B, Bonichon F, et al. Remarkable response to crizotinib in a woman with anaplastic lymphoma kinase-rearranged anaplastic thyroid carcinoma. J Clin Oncol. 2015;33:e84-e87.